Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the Central Nervous System (CNS). There are many forms of MS; although the majority are Relapsing Remitting (RRMS) representing approximately 80% of the cases. The disease appears to be more inflammatory in RRMS as manifested by an increase in Gadolinium (Gd) enhancement on MRI and an increase in inflammatory bio-assay markers.~Alemtuzumab; a humanized monoclonal antibody that targets the CD52 molecule present on T and B lymphocytes, natural killer (NK) cells, and monocytes and macrophages; effects rapid and sustained lymphocyte depletion and is approved for the treatment of B-cell chronic lymphocytic leukemia in many countries under the names CAMPATH or MabCAMPATH.~There are two parts to this Investigator Sponsored Trial (IST):~To perform advanced serial MRI studies on patients initiating alemtuzumab therapy.~To provide serum samples for the University of Southern California (USC) ICAM125 lymphocyte recovery study.
There are two parts to this investigator sponsored trial (IST):~To perform advanced serial MRI studies on patients initiating alemtuzumab therapy.~To provide serum samples for the University of Southern California (USC) ICAM125 lymphocyte recovery study.